# A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

> **NCT02252913** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 25 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Volitinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02252913
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252913, "A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02252913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*